Want to see VTRS full AI Analyst Report?
Top Page
Viatris
(NASDAQ:VTRS)
Select Model
Select Model
Rating:57Neutral
Price Target:
$16.50
▲(12.40% Upside)
Action:Reiterated
Date:07/02/26
VTRS scores slightly above average primarily because cash generation and balance-sheet refinancing provide financial flexibility, and the latest earnings call reinforced guidance with improving operational momentum (notably Greater China) and multiple upcoming catalysts. Offsetting these positives, the financial statements still show negative TTM net income and multi-year revenue drift, while valuation is constrained by a negative P/E despite a moderate dividend yield; technical signals remain broadly neutral.
Positive Factors
Cash generation & liquidity
Sustained positive operating cash flow and a multi-billion cash war chest provide durable financial flexibility. This supports debt service, dividends, targeted M&A or capex without relying on near-term profit improvement, insulating strategy from short-term earnings volatility.
Negative Factors
Negative trailing net income
Persistent negative TTM net income shows the business has not yet converted revenue and margin improvements into consistent GAAP profitability. That constrains retained earnings, weakens ROE, and limits long-term capacity to fund growth from internal profits without drawing on cash or issuing debt.
Read all positive and negative factors
Positive Factors
Negative Factors
Cash generation & liquidity
Sustained positive operating cash flow and a multi-billion cash war chest provide durable financial flexibility. This supports debt service, dividends, targeted M&A or capex without relying on near-term profit improvement, insulating strategy from short-term earnings volatility.
Read all positive factors
Viatris Key Performance Indicators (KPIs)
Any
Revenue by Segment
Breaks down revenue across different business segments, highlighting which areas are driving growth and which may need strategic adjustments.
Breaks down revenue across different business segments, highlighting which areas are driving growth and which may need strategic adjustments.
Data provided by:
The Fly
The FlyViatris (VTRS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$19.60B
Dividend Yield3.99%
Average Volume (3M)11.54M
Price to Earnings (P/E)―
Beta (1Y)0.99
Revenue Growth2.14%
EPS Growth91.93%
CountryUS
Employees32,000
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.26
Shares Outstanding1,173,682,000
10 Day Avg. Volume10,151,705
30 Day Avg. Volume11,542,455
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.99
Price to Sales (P/S)1.02
P/FCF Ratio7.52
Enterprise Value/Market Cap1.57
Enterprise Value/Revenue2.12
Enterprise Value/Gross Profit6.16
Enterprise Value/Ebitda12.03
Forecast
1Y Price Target
$17.60Price Target Upside19.89% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)2.46
Revenue Forecast (FY)$14.78B
Viatris Business Overview & Revenue Model
Company Description
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The comp...
How the Company Makes Money
Viatris primarily makes money by selling prescription medicines worldwide, generating revenue when its products are purchased by wholesalers, distributors, pharmacies, hospital systems, and government or institutional buyers (with pricing and volu...
Viatris Earnings Call Summary
Earnings Call Date:May 07, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 06, 2026
Earnings Call Sentiment Positive
The call portrayed solid operational performance and momentum: top-line revenue growth (3%), strong adjusted EBITDA expansion (10%), sizable China acceleration (+18%), meaningful pipeline progress with multiple upcoming regulatory catalysts, and robust cash flexibility (> $2.5B). These positives were tempered by regional softness (Europe, JANZ), supply constraints in lower-margin generics/ARV, ongoing regulatory timing uncertainty, and policy risk in China. On balance, the positives (broad-based execution, margin control, late-stage pipeline momentum and financial flexibility) outweigh the lowlights.Positive Updates
Revenue Growth and Profitability
Total revenues of $3.5 billion, up 3% year-over-year (operational basis); adjusted EBITDA of $1.0 billion (10% growth year-over-year) and adjusted EPS of $0.59, demonstrating improved earnings leverage versus revenue growth.
Negative Updates
Emerging Markets and Regional Softness
Emerging markets net sales were flat year-over-year, below company expectations; JANZ region net sales decreased ~2% (but came in above expectations) due to increased competition in Australia and government price regulation impact in Japan; Europe net sales declined approximately 1% driven by softer market conditions in select countries and competitive pressure on Dymista.
Read all updates
Q1-2026 Updates
Positive
Negative
Revenue Growth and Profitability
Total revenues of $3.5 billion, up 3% year-over-year (operational basis); adjusted EBITDA of $1.0 billion (10% growth year-over-year) and adjusted EPS of $0.59, demonstrating improved earnings leverage versus revenue growth.
Read all positive updates
Company Guidance
Viatris reaffirmed its 2026 guidance after a strong Q1 (total revenues $3.5B, +3% operational; adjusted EBITDA $1.0B; adjusted EPS $0.59; adjusted gross margin 56%; new product revenue $71M; cash generated $348M in Q1, or ~$459M excluding transaction/restructuring/taxes), and said full‑year revenue, adjusted EBITDA and adjusted EPS remain weighted about 52% to the second half with free cash flow also expected to be higher in H2; management now models stronger Greater China growth (mid‑ to high‑single digits, up from prior low‑single digits and +18% in Q1), more than $2.5B of cash available for deployment in 2026, a $140M dividend returned in Q1, an expected ~1% FX tailwind if current rates hold, and on‑track delivery of roughly $120M of cost savings this year while noting some temporary supply and generic competitive headwinds that may partially offset these tailwinds.Viatris Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
52
Neutral
Cash Flow
63
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 14.56B | 14.30B | 14.74B | 15.43B | 16.26B | 17.89B |
| Gross Profit | 5.01B | 5.01B | 5.62B | 6.44B | 6.50B | 5.58B |
| EBITDA | 2.57B | -395.40M | 2.82B | 3.52B | 6.43B | 4.48B |
| Net Income | -296.50M | -3.51B | -634.20M | 54.70M | 2.08B | -1.27B |
Balance Sheet | ||||||
| Total Assets | 36.83B | 37.19B | 41.50B | 47.69B | 50.02B | 54.84B |
| Cash, Cash Equivalents and Short-Term Investments | 1.80B | 1.45B | 1.09B | 1.18B | 1.47B | 935.00M |
| Total Debt | 14.34B | 14.70B | 14.31B | 18.37B | 19.53B | 23.36B |
| Total Liabilities | 22.18B | 22.48B | 22.87B | 27.22B | 28.95B | 34.35B |
| Stockholders Equity | 14.66B | 14.71B | 18.64B | 20.47B | 21.07B | 20.49B |
Cash Flow | ||||||
| Free Cash Flow | 1.71B | 1.94B | 1.98B | 2.33B | 2.51B | 2.51B |
| Operating Cash Flow | 2.17B | 2.32B | 2.30B | 2.80B | 3.00B | 3.02B |
| Investing Cash Flow | -85.20M | -427.70M | 1.80B | -764.10M | 1.47B | -117.80M |
| Financing Cash Flow | -1.03B | -1.29B | -4.33B | -2.30B | -3.88B | -3.01B |
Viatris Technical Analysis
Positive
14.68
Price Trends
15.94
Positive
15.09
Positive
13.05
Positive
Market Momentum
0.10
Negative
60.04
Neutral
78.53
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VTRS, the sentiment is Positive. The current price of 14.68 is below the 20-day moving average (MA) of 16.02, below the 50-day MA of 15.94, and above the 200-day MA of 13.05, indicating a bullish trend. The MACD of 0.10 indicates Negative momentum. The RSI at 60.04 is Neutral, neither overbought nor oversold. The STOCH value of 78.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VTRS.
Viatris Risk Analysis
Viatris disclosed 17 risk factors in its most recent earnings report. Viatris reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Viatris Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | $1.96B | 20.93 | 17.32% | ― | 37.03% | ― | |
67 Neutral | $12.04B | 26.17 | 11.76% | 0.64% | -1.06% | -26.71% | |
61 Neutral | $37.14B | 23.15 | 20.79% | ― | 5.76% | ― | |
59 Neutral | $5.48B | 45.26 | -144.72% | ― | 7.62% | ― | |
57 Neutral | $19.60B | -63.28 | -1.97% | 3.99% | 2.14% | 91.93% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $1.52B | -0.84 | -50.65% | 8.48% | -3.62% | -932.84% |
* Healthcare Sector Average
VTRS
Viatris
16.70
7.85
88.68%
RDY
Dr Reddy's Laboratories
14.38
-0.63
-4.17%
PRGO
Perrigo Company
11.02
-13.62
-55.27%
TEVA
Teva Pharmaceutical
34.64
17.79
105.58%
ANIP
ANI Pharmaceuticals
86.03
21.12
32.54%
AMRX
Amneal Pharmaceuticals
17.15
8.74
103.92%
Viatris Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Viatris Secures New ¥40 Billion Term Loan Facility
Positive
Jul 1, 2026
On July 1, 2026, Viatris Inc. entered into an amended and restated term loan credit agreement with a syndicate of lenders led by Mizuho Bank, establishing a ¥40 billion senior unsecured term loan facility to support general corporate purposes...
Business Operations and StrategyPrivate Placements and Financing
Viatris Issues €650 Million Senior Notes to Refinance Debt
Positive
Jun 18, 2026
On June 17, 2026, Viatris Inc. completed a €650 million public offering of 4.250% senior unsecured notes due 2033, guaranteed by key subsidiaries including Mylan Inc. and Utah Acquisition Sub Inc. The notes, issued under an existing indentur...
Private Placements and Financing
Viatris Issues €650 Million Senior Notes in Europe
Positive
Jun 15, 2026
On June 12, 2026, Viatris Inc. entered into an underwriting agreement with a syndicate of banks led by BNP Paribas, Citigroup Global Markets Limited and Goldman Sachs Co. LLC to issue €650 million of 4.250% senior notes due 2033. The notes ...
Executive/Board ChangesShareholder Meetings
Viatris Shareholders Approve Directors, Pay and Auditor
Positive
May 15, 2026
On May 15, 2026, Viatris Inc. held its 2026 annual meeting of shareholders, where investors voted on board membership, executive compensation and the company’s external auditor. Shareholders elected thirteen director nominees to serve until ...
Business Operations and StrategyFinancial Disclosures
Viatris Delivers Strong Q1 2026 Results, Reaffirms Guidance
Positive
May 7, 2026
On May 7, 2026, Viatris reported first-quarter 2026 results showing total revenues of $3.52 billion, up 8% year-on-year on a reported basis and 3% operationally, with U.S. GAAP net earnings of $176 million and adjusted EBITDA of $1.0 billion, up 1...
Executive/Board Changes
Viatris Names Paul Campbell Interim Chief Financial Officer
Neutral
May 4, 2026
On May 1, 2026, Viatris said Chief Financial Officer Theodora “Doretta” Mistras had voluntarily resigned to pursue another opportunity, with her CFO role ending May 8 and her employment concluding May 22, after a transition period. The...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.